Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy P Hughes

Showing results (121-130 of 205) with videos related to

Pageof 21
Sort By:
Haematologica|May 2, 2016
Chronic myeloid leukemia: reminiscences and dreamsTariq I Mughal, Jerald P Radich, Michael W Deininger, et al.
Leukemia|February 21, 2020
Aberrant RAG-mediated recombination contributes to multiple structural rearrangements in lymphoid blast crisis of chronic myeloid leukemiaDaniel W Thomson, Nur Hezrin Shahrin, Paul P S Wang, et al.
Blood|December 24, 2013
Monoclonal antibody targeting of IL-3 receptor α with CSL362 effectively depletes CML progenitor and stem cellsEva Nievergall, Hayley S Ramshaw, Agnes S M Yong, et al.
Journal of Hematology & Oncology|December 19, 2024
Asciminib add-on to imatinib demonstrates sustained high rates of ongoing therapy and deep molecular responses with prolonged follow-up in the ASC4MORE studyTimothy P Hughes, Giuseppe Saglio, Jan Geissler, et al.
British Journal of Haematology|July 31, 2020
High-risk B-cell acute lymphoblastic leukaemia presenting with hypereosinophilia and acquiring a novel PAX5 fusion on relapseBarbara J McClure, Susan L Heatley, Jacqueline Rehn, et al.
Cancer Chemotherapy and Pharmacology|May 25, 2012
Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemiaOphelia Q P Yin, Frank J Giles, Michele Baccarani, et al.
Blood|June 7, 2024
Asciminib is a novel inhibitor of ABL1 and ABL2 gene fusions in ALL but requires the ABL SH3 domain for efficacyLaura N Eadie, Elias Lagonik, Elyse C Page, et al.
Oncogene|December 3, 2021
HMGN1 plays a significant role in CRLF2 driven Down Syndrome leukemia and provides a potential therapeutic target in this high-risk cohortElyse C Page, Susan L Heatley, Laura N Eadie, et al.
Blood|September 26, 2009
Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutationsMartin C Müller, Jorge E Cortes, Dong-Wook Kim, et al.
European Journal of Clinical Pharmacology|December 31, 2011
Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phaseRichard A Larson, Ophelia Q P Yin, Andreas Hochhaus, et al.
Pageof 21

Showing results (121-130 of 205) with videos related to

Sort By:
Pageof 21
Haematologica|May 2, 2016
Chronic myeloid leukemia: reminiscences and dreamsTariq I Mughal, Jerald P Radich, Michael W Deininger, et al.
Leukemia|February 21, 2020
Aberrant RAG-mediated recombination contributes to multiple structural rearrangements in lymphoid blast crisis of chronic myeloid leukemiaDaniel W Thomson, Nur Hezrin Shahrin, Paul P S Wang, et al.
Blood|December 24, 2013
Monoclonal antibody targeting of IL-3 receptor α with CSL362 effectively depletes CML progenitor and stem cellsEva Nievergall, Hayley S Ramshaw, Agnes S M Yong, et al.
Journal of Hematology & Oncology|December 19, 2024
Asciminib add-on to imatinib demonstrates sustained high rates of ongoing therapy and deep molecular responses with prolonged follow-up in the ASC4MORE studyTimothy P Hughes, Giuseppe Saglio, Jan Geissler, et al.
British Journal of Haematology|July 31, 2020
High-risk B-cell acute lymphoblastic leukaemia presenting with hypereosinophilia and acquiring a novel PAX5 fusion on relapseBarbara J McClure, Susan L Heatley, Jacqueline Rehn, et al.
Cancer Chemotherapy and Pharmacology|May 25, 2012
Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemiaOphelia Q P Yin, Frank J Giles, Michele Baccarani, et al.
Blood|June 7, 2024
Asciminib is a novel inhibitor of ABL1 and ABL2 gene fusions in ALL but requires the ABL SH3 domain for efficacyLaura N Eadie, Elias Lagonik, Elyse C Page, et al.
Oncogene|December 3, 2021
HMGN1 plays a significant role in CRLF2 driven Down Syndrome leukemia and provides a potential therapeutic target in this high-risk cohortElyse C Page, Susan L Heatley, Laura N Eadie, et al.
Blood|September 26, 2009
Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutationsMartin C Müller, Jorge E Cortes, Dong-Wook Kim, et al.
European Journal of Clinical Pharmacology|December 31, 2011
Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phaseRichard A Larson, Ophelia Q P Yin, Andreas Hochhaus, et al.
Pageof 21